Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEK | Q02763 | 3/20 | 0.50 |
| ▸ | ZAP70 | P43403 | 2/20 | 0.50 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.50 |
| ▸ | BRAF | P15056 | 3/20 | 0.46 |
| ▸ | CDK8 | P49336 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 3/20 | 0.45 |
| ▸ | SYK | P43405 | 3/20 | 0.45 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.45 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MPO | P05164 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | GMNN | O75496 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TTR | P02766 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1056393 | 0.85 | ZAP70 (0.60) | TEKZAP70LRRK2BRAFKDR | |
| SCHEMBL1057075 | 0.83 | BRAF (0.55) | TEKZAP70LRRK2BRAFSYK | |
| SCHEMBL1058856 | 0.83 | LRRK2 (0.52) | TEKZAP70LRRK2BRAFSYK | |
| SCHEMBL1060239 | 0.83 | ZAP70 (0.73) | TEKZAP70LRRK2BRAFSYK | |
| SCHEMBL1058358 | 0.82 | ZAP70 (0.57) | TEKZAP70LRRK2BRAFSYK | |
| SCHEMBL1051527 | 0.80 | ZAP70 (0.52) | TEKZAP70LRRK2BRAFKDR | |
| SCHEMBL1058768 | 0.78 | SYK (0.65) | ZAP70LRRK2SYKJAK2 | |
| SCHEMBL1057690 | 0.78 | SYK (0.65) | ZAP70LRRK2SYKJAK2 | |
| SCHEMBL1053635 | 0.77 | LRRK2 (0.54) | TEKZAP70LRRK2BRAFCYP1A2 | |
| SCHEMBL1060196 | 0.77 | ZAP70 (0.53) | ZAP70LRRK2BRAFKDRSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8354526-B2 | Pyrido [4, 3-D] pyrimidinone derivatives as kinase inhibitors | IRM LLC (BM) | 2013-01-15 | — | — | US | claimed |
| US-20110003790-A1 | PYRIDO [4, 3-D] PYRIMIDINONE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2011-01-06 | — | — | US | claimed |
| EP-2250169-A1 | PYRIDO [4, 3-D]PYRIMIDINONE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2010-11-17 | — | — | EP | claimed |
| WO-2009099801-A1 | PYRIDO [4, 3-D] PYRIMIDINONE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2009-08-13 | — | — | WO | claimed |
| US-8354526-B2 | Pyrido [4, 3-D] pyrimidinone derivatives as kinase inhibitors | IRM LLC (BM) | 2013-01-15 | — | — | US | disclosed |
| US-20110003790-A1 | PYRIDO [4, 3-D] PYRIMIDINONE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2011-01-06 | — | — | US | disclosed |
| EP-2250169-A1 | PYRIDO [4, 3-D]PYRIMIDINONE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2010-11-17 | — | — | EP | disclosed |
| WO-2009099801-A1 | PYRIDO [4, 3-D] PYRIMIDINONE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003790-A1 | PYRIDO [4, 3-D] PYRIMIDINONE DERIVATIVES AS KINASE INHIBITORS | ZAP70, FLT3, LCK | TEK 94/4885ZAP70 1/4885LRRK2 1470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.